Elite in Choroideremia

Mariya Moosajee

London, ENG, GB 
Elite in Choroideremia
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Mariya Moosajee practices in London, United Kingdom. Ms. Moosajee is rated as an Elite expert by MediFind in the treatment of Choroideremia. Her top areas of expertise are Charles Bonnet Syndrome, Choroideremia, Microphthalmia, Vitrectomy, and Cataract Removal.

Her clinical research consists of co-authoring 166 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 16 articles in the study of Choroideremia.

Gender
Female

Locations

London, ENG, United Kingdom
Other Locations
Bristol, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss
Enrollment Status: Terminated
Publish Date: August 07, 2024
Intervention Type: Drug, Other
Study Drug: QR-421a
Study Phase: Phase 2/Phase 3
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
Enrollment Status: Terminated
Publish Date: July 12, 2024
Intervention Type: Drug, Other
Study Drug: Ultevursen
Study Phase: Phase 2/Phase 3
View 1 Less Clinical Trial

166 Total Publications

Genome-Wide Insights Into the Genes and Pathways Shaping Human Foveal Development: Redefining the Genetic Landscape of Foveal Hypoplasia.
Genome-Wide Insights Into the Genes and Pathways Shaping Human Foveal Development: Redefining the Genetic Landscape of Foveal Hypoplasia.
Journal: Investigative ophthalmology & visual science
Published: September 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Moosajee's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 16 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile